Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.

JAMA ophthalmology - 1 Apr 2020

Kim Ryan S, Yaghy Antonio, Wilde Lindsay R, Shields Carol L

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Aniline Compounds
Share to Fatal Outcome
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Pyrazines

Share to Uveal Neoplasms

Share to Visual Acuity

Source

Identifiers

PMID: 32163103
DOI: 10.1001/jamaophthalmol.2020.0110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.PMID 32163103Read ↗

Successful treatment with gilteritinib for popliteal extramedullary relapse of FLT-3-ITD acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation : a case report and literature reviewSemantic proximity Read ↗

Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the FieldSemantic proximity Read ↗

Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.Semantic proximity Read ↗

Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.Semantic proximity Read ↗

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.Semantic proximity Read ↗

Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.Semantic proximity Read ↗

Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.Semantic proximity Read ↗

Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.Semantic proximity Read ↗

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML PatientsSemantic proximity Read ↗

Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients.Semantic proximity Read ↗

Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.Semantic proximity Read ↗

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.